Publications by Healthy Skepticism Members
This page lists 210 publications relevant to drug promotion where at least one of the authors is a Healthy Skepticism member. However some of the authors below have no conection with Healthy Skepticism other than being co-author on a publication with one of our members.
Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.
HSL14309
Jureidini JN, McHenry LB, Mansfield PR.
Clinical trials and drug promotion: Selective reporting of study 329
The International Journal of Risk and Safety in Medicine 2008 May;20(1-2):73-81
Link to source with long URL
HSL14273
Ross JS, Hill KP, Egilman DS, Krumholz HM.
Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.
JAMA 2008 Apr 16;299(15):1800-12
http://jama.ama-assn.org/cgi/content/full/299/15/1800
HSL13857
Vitry A, Lexchin J, Sasich L, Dupin-spriet T, Reed T, Bertele V, Garattini S, Toop L, Hurley E.
Provision of information on regulatory authorities’ websites
Internal Medicine Journal 2008 Mar 11(15):epub ahead of print
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1445-5994.2007.01588.x
HSL13924
De Maeseneer J, Van Weel C, Egilman D, Mfenyana K, Kaufman A, Sewankambo N, Flinkenflögel M.
Funding for primary health care in developing countries
BMJ 2008 Mar 8;336(7643):518
http://www.bmj.com/cgi/content/extract/336/7643/518
HSL13722
Othman N.
Promosi ubat-ubatan: Adakah keuntungan mengaburi kualiti informasi? [Pharmaceutical promotion: Does the drive for profits reduce the quality of information?]
Dewan Kosmik 2008 Mar(7643):25-26
HSL13443
Jutel A, Menkes DB.
Soft Targets: Nurses and the Pharmaceutical Industry
PLoS Medicine 2008 Feb 5;5(2):5
Link to source with long URL
HSL13667
Herxheimer A, Sanz E.
Social, cultural and ethical aspects of drug use—changes over 40 years: a personal look back
European Journal of Clinical Pharmacology 2008 Feb;64(2):107-114
http://www.springerlink.com/content/u2rn52n6x15x71h6/fulltext.html
HSL12980
Mansfield PR.
Do advertisements in clinical software influence prescribing?
Med J Aust 2008 Jan 7;188(1):13-14
http://www.mja.com.au/public/issues/188_01_070108/man11083_fm.html
HSL12974
Gagnon M-A, Lexchin J.
The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States
PLoS Medicine 2008 Jan 3;5(1)
Link to source with long URL
HSL12982
Harvey K, Korczak VS, Marron LJ, Newgreen DB.
Commercialism, choice and consumer protection: regulation of complementary medicines in Australia
The Medical Journal of Australia 2008;188(1):21-25
http://www.mja.com.au/public/issues/188_01_070108/har10522_fm.html
HSL12821
Jureidini J.
The Black Box Warning: Decreased Prescriptions and Increased Youth Suicide?
Am J Psychiatry 164:1907, December 2007 2007 Dec;164(12):1907
http://ajp.psychiatryonline.org/cgi/content/full/164/12/1907
HSL14193
Moncrieff J.
The Myth of the Chemical Cure: A Critique of Psychiatric Drug Treatment
: Palgrave Macmillan; 2007(12)
http://www.palgrave.com/products/title.aspx?PID=283272
HSL12817
Leo J, Lacasse JR.
The Media and the Chemical Imbalance Theory of Depression
Society 2007 Nov 28(12):epub ahead of print
http://www.springerlink.com/content/u37j12152n826q60/fulltext.html
HSL12580
Bala-Miller P, Macmullan J, Upchurch L
Drugs, doctors and dinners: How drug companies influence health in the developing world
London: Consumers International; 2007 Oct 31(12)
http://marketingoverdose.org/documents/ci_pharma_2007.pdf
HSL13916
Nordin C.
The pharmaceutical industry and doctors' prescribing habits
Ockham's Razor (Radio National, Australian Broadcasting Commission) 2007 Oct 14(12)
http://www.abc.net.au/rn/ockhamsrazor/stories/2007/2056879.htm
HSL12354
Toop L, Mangin D.
Industry funded patient information and the slippery slope to New Zealand
BMJ 2007 Oct 6;335(7622):694
http://www.bmj.com/cgi/content/short/335/7622/694?etoc
HSL12474
Vitry A, Lexchin J, Mansfield PR.
Is Australia's National Medicines Policy Failing? The Case of Cox-2 Inhibitors
Int J Health Serv 2007 Oct;37(4):735 - 744
Link to source with long URL
HSL12539
Light D.
Misleading Congress about Drug Development
Journal of Health Politics, Policy and Law 2007 Oct;32(5):895-913
http://bioethics.upenn.edu/people/?last=Light&first=Donald
HSL12268
Allan GM, Lexchin J, Wiebe N.
Physician Awareness of Drug Cost: A Systematic Review
PLoS Med 2007 Sep 25;4(9):e283
Link to source with long URL
HSL12160
Egilman D.
The Truth Is Not Free
The Pump Handle 2007 Sep 11(9)
http://thepumphandle.wordpress.com/2007/09/11/the-truth-is-not-free/
HSL12102
Norsigian J, Stephenson H.
HPV Vaccine Flags Need for More Pap Tests
Women's eNews 2007 Sep 5(9)
http://www.womensenews.org/article.cfm?aid=3303
HSL12084
Mansfield P.
Xenical, the drug that dare not speak its name
Crikey 2007 Sep 3(9)
Link to source with long URL
HSL12169
Vitry A, Mintzes B, Lexchin J
Direct-to-consumer advertising policy in Australia: realism in whose interests?
Internal Medicine Journal 2007 Sep;37(9):665–666
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1445-5994.2007.01447.x
HSL12855
Lexchin J.
The secret things belong unto the Lord our God: secrecy in the pharmaceutical arena.
Med Law 2007 Sep;26(3):417-30
Link to source with long URL
HSL12070
Mansfield P.
Pharma pays the piper: will Roche call Kidney Health Australia’s tune?
Crikey 2007 Aug 28(3)
Link to source with long URL
HSL11943
Menkes DB, Jureidini JN, Mansfield PR.
Skepticism about antidepressants for under 18s
BMJ Rapid Response 2007 Aug 22(3):epub
http://www.bmj.com/cgi/eletters/335/7615/329#175023
HSL11845
Mangin D, Sweeney K, Heath I.
Preventive health care in elderly people needs rethinking
BMJ 2007 Aug 11;335(7614):285
http://www.bmj.com/cgi/content/full/335/7614/285
HSL11932
Spurling G, Mansfield P.
General practitioners and pharmaceutical sales representatives: quality improvement research.
Qual Saf Health Care 2007 Aug;16(4):266-70
http://qshc.bmj.com/cgi/content/full/16/4/266
HSL11672
Biles D, Howlett P, Hughes R.
Journals and drug advertising: Medical schools, take the lead
BMJ 2007 Jul 28;335(7612):172
http://www.bmj.com/cgi/content/full/335/7612/172-a
HSL11746
Light DW.
Is G8 putting profits before the world's poorest children?
The Lancet 2007 Jul 28;370(9584):297-298
Link to source with long URL
HSL11250
Jureidini JN.
Not a trial of antidepressants
BMJ 2007 Jun 18(9584):epub
http://www.bmj.com./cgi/eletters/bmj.39224.494340.55v1
HSL11109
Harvey K.
Conduct becoming? GPs' GlaxoSmithKline degustation
Crikey 2007 Jun 14(9584)
Link to source with long URL
HSL11097
Harvey KJ, Harris AH, Bulfone L.
The National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2007: reform or fracture?
Med J Aust 2007 Jun 13;187(4):206-207
http://www.mja.com.au/public/issues/187_04_200807/har10641_fm.html
HSL12408
Faunce TA, Lexchin J.
'Linkage' pharmaceutical evergreening in Canada and Australia.
Aust New Zealand Health Policy 2007 Jun 1;4(1):8
http://www.anzhealthpolicy.com/content/4/1/8
HSL10868
Norsigian J.
Misleading Ads and How They Hurt Us
The Women's Media Center 2007 May 25(1)
http://www.womensmediacenter.com/ex/052207.html
HSL10750
Mansfield PR.
The illusion of invulnerability
BMJ 2007 May 19;334(7602):1020
http://www.bmj.com/cgi/content/full/334/7602/1020-c
HSL10636
Mansfield PR.
The illusion of invulnerablity
BMJ 2007 May 6;334(7600):epub
http://www.bmj.com/cgi/eletters/334/7600/934#164939
HSL10002
Harvey K.
Schwabe Pharma Australia & Natural Health Products - litigation update
AusPharmList (subscription required) 2007 Apr 5(7600)
http://www.auspharmlist.net.au/post.php?postid=9858
HSL10735
Cheng AC, Robinson PM, Harvey K.
Off-label use of medicines: consensus recommendations for evaluating appropriateness.
Med J Aust 2007 Apr 2;186(7):379-80
http://www.mja.com.au/public/issues/186_07_020407/letters_020407_fm-2.html
HSL14061
Roy N, Madhiwalla N, Pai SA.
Drug promotional practices in Mumbai: a qualitative study
Indian Journal of Medical Ethics 2007 Apr-Jun;4(2):57-61
http://www.ijme.in/152oa57.html
HSL10470
Menkes DB, Maharajh M.
Just saying 'no' to pharmaceutical sponsorship
N Z Med J 2007 Mar 23;120(1251):U2471
Link to source with long URL
HSL11455
Rogers , W.a.
The tangled web of medical and commercial interests
Health Expectations 2007 Mar;10(1):1-3
HSL12681
Spurling G, Kyle G.
Is your sample cupboard relevant to your practice?
Aust Fam Physician 2007 Mar;36(3):187-8,
Link to source with long URL
HSL9382
Mansfield PR, Hoffman JR, Lexchin J.
Educating Health Professionals about Drug and Device Promotion: Authors' Reply.
PLoS Med. 2007 Feb 27;4(2):e88
Link to source with long URL
HSL9245
Harvey K.
Medicines Australia latest Code of Conduct Report
AusPharmList 2007 Feb 16(2)
http://auspharmlist.net.au/post.php?postid=9292
HSL11694
Moncrieff J.
In Debate: Are Antidepressants as Effective as Claimed? No, They Are Not Effective at All
Can J Psychiatry 2007 Feb;52(2):96–97
http://publications.cpa-apc.org/media.php?mid=328
HSL10641
Lexchin J.
Of Money and Trust in Biomedical Care
Mens Sana Monographs 2007 Jan-Dec;5(1):7-10
Link to source with long URL
HSL10681
Guyatt G, Devereaux PJ, Lexchin J, Stone SB, Yalnizyan A, Himmelstein D, Woolhandler S, Zhou Q, Goldsmith G, Cook DJ, Haines T, Lacchetti C, Lavis J, Sullivan T, Mills E, Kraus S, Bhatnagar N.
A systematic review of studies comparing health outcomes in Canada and the United States
Open Medicine 2007;1(1):E27-36
http://www.openmedicine.ca/article/view/8/1
HSL9163
Lexchin J.
A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences.
Health Policy 2006 Dec;79(2-3):214-20
http://linkinghub.elsevier.com/retrieve/pii/S0168-8510(06)00003-0
HSL9160
Mansfield PR.
Doctors as lapdogs to drug firms: Independence may be most cost effective way to improve health care.
BMJ 2006 Nov 25;333(7578):1121-2
http://www.bmj.com/cgi/content/full/333/7578/1121-c
HSL6631
Healy D, Herxheimer A, Menkes D.
Antidepressants and Violence: Problems at the Interface of Medicine and Law
PLoS 2006 Sep 13(7578)
Link to source with long URL
HSL6640
Korczak V.
What's wrong with pushing pills?
New Matilda 2006 Sep 8(7578)
Link to source with long URL
HSL6350
Harvey K.
Drug companies' free lunches have expensive side-effects
New Matilda 2006 Aug 4(7578)
http://www.newmatilda.com.au/policytoolkit/policydetail.asp?PolicyID=462
HSL6143
Mansfield PR.
Another way to tame the monster
BMJ 2006 Jul 22;333(7560):202
http://bmj.bmjjournals.com/cgi/content/short/333/7560/202-a?etoc%3e
HSL6127
Mansfield PR.
A more comprehensive alternative
PLoS Med 2006 Jul 18;3(7):306
Link to source with long URL
HSL6047
Lexchin J.
Risks and benefits of the profit motive in the pharmaceutical industry
Agora Vox 2006 Jul 11(7)
http://www.agoravox.com/article.php3?id_article=4957
HSL6010
Mansfield PR.
Rapid responses: A more comprehensive and achievable alternative
BMJ 2006 Jul 8;333(7)
http://bmj.bmjjournals.com/cgi/eletters/333/7558/0-f
HSL9165
Lexchin J, Williams R, Marion J.
Rebuttal: are drugs too expensive in Canada?
Can Fam Physician 2006 Jul;52:841-2,(7)
Link to source with long URL
HSL5800
Lexchin J, Wright D.
Commercial influence and the content of medical journals
BMJ 2006 Jun 17(7)
http://bmj.bmjjournals.com/cgi/content/full/332/7555/1444
HSL5726
Lexchin J, Light DW.
Commercial influence and the content of medical journals.
BMJ 2006 Jun 17;332(7555):1444-7
http://bmj.bmjjournals.com/cgi/content/short/332/7555/1444?etoc
HSL5478
Mira AJ, Isely W, McDonnell M, Huch KM, Whittle HM, Nugent TJ, Lack DZ
Readers' Responses to "Physicians on the Take"
MedGenMed 2006 May 12(7555)
http://www.medscape.com/viewarticle/531612?src=mp
HSL5025
McConnell M.
An open letter to Healthy Skepticism:
2006 May 3(7555)
HSL6329
Lexchin J.
Are drugs too expensive in Canada? Yes
Can Fam Physician. 2006 May 01;52(7555):573-6, 578-81
http://www.cfpc.ca/cfp/2006/May/vol52-may-debates-1.asp
HSL10642
Lexchin J.
Who Should Own the Presses?
Israeli Journal of Emergency Medicine 2006 May;6(2):3-5
http://www.isrjem.org/Lexchin.Editorial.proof2.pdf
HSL5496
Biron P, Mintzes B, Lexchin J.
Questions about Adderall XR.
CMAJ 2006 Apr 25;174(9):1303-4
http://www.cmaj.ca/cgi/content/full/174/9/1303-a
HSL4397
A Collection of Articles on Disease Mongering
PLoS Medicine ( Public Library of Science) 2006 Apr 11(9)
http://collections.plos.org/diseasemongering-2006.php
HSL4398
Henry D, Moynihan R.
Inaugural Conference on Disease-Mongering
diseasemongering.org 2006 Apr 11(9)
http://www.diseasemongering.org/
HSL5499
Lexchin J.
Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices
CMAJ 2006 Apr 11;174(8):1120-1
http://www.cmaj.ca/cgi/content/full/174/8/1120
HSL6012
Mansfield PR.
Universal Hepatitis-B Vaccination in India: A Questionable Strategy
BMJ 2006 Apr 7;302(8)
http://bmj.bmjjournals.com/cgi/eletters/332/7545/804
HSL9164
Roughead EE, Lexchin J.
Adverse drug events: counting is not enough, action is needed.
Med J Aust 2006 Apr 3;184(7):315-6
http://www.mja.com.au/public/issues/184_07_030406/rou10066_fm.html
HSL6011
Mansfield PR, Phadke A, Kale A.
Blanket hepatitis B vaccination is questionable in India
BMJ 2006 Apr 1;332(7547):976
HSL4392
Jureidini J.
Systematic checks can avert crisis from adverse drug reactions
The Australian Newspaper 2006 Apr 1(7547)
Link to source with long URL
HSL8507
Lexchin J.
Bigger and Better: How Pfizer Redefined Erectile Dysfunction
PLoS Med 2006 Apr;3(4)
Link to source with long URL
HSL4381
Almasi E, Stafford R, Kravitz RL, Mansfield PR.
What Are the Public Health Effects of Direct-to-Consumer Drug Advertising?
PLoS Medicine 2006 Mar 28;3(3):e145
Link to source with long URL
HSL5692
Lexchin J .
Withdrawals of drugs for safety reasons: How do regulators decide if they are too unsafe?
Reaction Bulletin 2006 Feb 1;236(3)
HSL9162
Lexchin J.
Is there still a role for spontaneous reporting of adverse drug reactions?
CMAJ 2006 Jan 17;174(2):191-2
http://www.cmaj.ca/cgi/content/full/174/2/191
HSL6974
Tonkin AL, Taverner D, Latte J, Doecke C.
The Effect of an Interactive Tutorial on the Prescribing Performance of Senior Medical Students
Med Educ. 2006(2)
HSL7015
Mansfield PR, Lexchin J, Wen LS, Grandori L, McCoy CP, Hoffman JR, Ramos J, Jureidini JN.
Educating Health Professionals about Drug and Device Promotion: Advocates' Recommendations
PLoS Med 2006;3(11):e451
Link to source with long URL
HSL7016
Mansfield P.
Industry-Sponsored Research: A More Comprehensive Alternative.
PLoS Med 2006;3(10):e463
Link to source with long URL
HSL8918
Cohen JC, Illingworth P, Schuklenk U, Eds .
The Power of Pills
London: Pluto Press; 2006(10)
Link to source with long URL
HSL9161
Jureidini J, Tonkin A.
Overuse of antidepressant drugs for the treatment of depression.
CNS Drugs 2006;20(8):623-32
Link to source with long URL
HSL12571
Light D.
Basic research funds to discover important new drugs: who contributes how much?
Burke MA, De Francisco A. Monitoring Financial Flows for Health Research 2005: Behind the Global Numbers Geneva: Global Forum for Health Research; 2006(8)
http://bioethics.upenn.edu/people/?last=Light&first=Donald
HSL3417
Harvey K.
Submission to ACCC re: Application A90994-6 by Medicines Australia re revised Code of Conduct [15th Ed]
Medreach ( www.medreach.com.au ) 2005 Dec 14(8)
http://www.accc.gov.au/content/index.phtml/itemId/716327
HSL3946
Norris P, Herxheimer A, Lexchin J, Mansfield P.
Drug Promotion: What we know, what we have yet to learn.
Geneva: World Health Organisation and Health Action International; 2005 Dec(8)
http://www.haiweb.org/18012006/drugPromodhai12sept.pdf
HSL3111
Light D, Lexchin J.
US drug prices not Canada's fault, study says
York University 2005 Oct 22(8)
http://www.yorku.ca/mediar/archive/Release.asp?Release=966
HSL10643
Light DW, Lexchin J.
Foreign free riders and the high price of US medicines.
BMJ 2005 Oct 22;331(7522):958-60
http://www.bmj.com/cgi/content/full/331/7522/958
HSL3036
Goodman, B
Pictures at an Exhibition: The 2005 American Academy of Family Practice Annual Meeting, San Francisco, California
No Free Lunch 2005 Oct 2(7522)
http://nofreelunch.org/news.htm
HSL10644
Lexchin J.
Commentary: Nesiritide and Lessons Unlearned
Israeli Journal of Emergency Medicine 2005 Oct;5(4):69-72
http://www.isrjem.org/NesiritideOct05.pdf
HSL6013
Mansfield PR.
Response to Jeffrey Mann: Clinical trials never produce certainty
BMJ 2005 Sep 16;331(4)
http://bmj.bmjjournals.com/cgi/eletters/331/7516/528
HSL6014
Mansfield PR.
Celecoxib causes excess cardiovascular events and illustrates the folly of allowing drug sellers too much power.
BMJ 2005 Sep 10;331(4)
http://bmj.bmjjournals.com/cgi/eletters/331/7516/528
HSL3942
Mansfield PR.
Banning all drug promotion is the best option pending major reforms.
J Bioethical Inquiry 2005;2(2):16-22
HSL6015
Mansfield PR, Tonkin AL, Jureidini JN.
Fluoxetine for depressed adolescents: harms likely to exceed benefits
BMJ 2005 May 28;330(2)
http://bmj.bmjjournals.com/cgi/eletters/330/7493/730-b
HSL2266
Harvey KJ, Vitry AI., Aroni R, Ballenden N, Faggotter R.
Pharmaceutical advertisements in prescribing software: an analysis
MJA 2005 Jul 18;183(2):75-79
http://www.mja.com.au/public/issues/183_02_180705/har10263_fm.html
HSL1945
Mansfield PR.
Response to Pfizer
BMJ 2005 Jun 27(2)
http://bmj.bmjjournals.com/cgi/eletters/328/7444/879#110681
HSL6412
Toop L, Richards D, Dowell T.
Response to Maubach and Hoek's paper on GP attitudes to DTCA
N Z Med J. 2005 Jun 24;118(1217):U1543
HSL1978
Stocks N, Allan J, Mansfield PR.
Management of hyperlipidaemia.
Aust Fam Physician 2005 Jun;34(6):447-53
http://www.racgp.org.au/document.asp?id=17049
HSL8672
Mintzes B, Barer M, Lexchin J, Bassett KL.
Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy.
Res Social Adm Pharm 2005 Jun;1(2):310-30
Nil
HSL1768
Dinant G-J, Mansfield P.
Van zoete koek naar gezonde scepsis: De houding van huisartsen tegenover geneesmiddelenreclame
Huisarts Wet 2005 May 2;48(6):304-307
Link to source with long URL
HSL6144
Shann F.
Non-specific effects of vaccination: vaccines have non-specific (heterologous) effects.
BMJ 2005 Apr 9;330(7495):844
http://bmj.bmjjournals.com/cgi/content/full/330/7495/844
HSL803
Mansfield PR, Vitry A.
Rofecoxib withdrawal.
Australian Prescriber 2005 Apr;28(2):30
Link to source with long URL
HSL1219
Lexchin J.
Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
CMAJ 2005 Mar 15;172(6):765-7
http://www.cmaj.ca/cgi/content/full/172/6/765
HSL1168
Raven M, Rogers W, Jureidini J.
Partnerships between academic psychiatry and the pharmaceutical industry.
Australas Psychiatry 2005 Mar;13(1):83-4
Link to source with long URL
HSL1890
Mansfield PR.
Beliefs and plans of GP registrars before and after a 90 minute talk about drug promotion
Unpublished 2005 Feb 25(1)
HSL371
Mansfield PR, Vitry AI, Wright JM.
Withdraw all COX-2-selective drugs.
Med J Aust 2005 Feb 21;182(4):197
Link to source with long URL
HSL1218
Lexchin J.
Prescribing errors
CMAJ 2005 Jan 18;172(2)
http://www.cmaj.ca/cgi/content/full/172/2/229
HSL1220
Lexchin J, Cassels A.
Does the C in CME stand for "Continuing" or "Commercial"?
CMAJ 2005 Jan 18;172(2):160-2
http://www.cmaj.ca/cgi/content/full/172/2/160-a
HSL2383
Mansfield PR, Mintzes B, Richards D, Toop L.
Direct to consumer advertising.
BMJ 2005 Jan 1;330(7481):5-6
http://bmj.bmjjournals.com/cgi/content/full/330/7481/5
HSL1223
Lexchin JR.
Implications of pharmaceutical industry funding on clinical research.
Ann Pharmacother 2005 Jan;39(1):194-7
http://www.theannals.com/cgi/content/full/39/1/194
HSL5965
Jureidini JN, Tonkin A.
Suicide and antidepressants in children (editorial)
Australian Prescriber 2005;28(1):110-1
http://www.australianprescriber.com/magazine/28/5/110/1/
HSL6132
Mansfield PR, Raven MK, Jureidini JN.
Depressed youth, suicidality and antidepressants
MJA 2005;183(5):275-276
http://www.mja.com.au/public/issues/183_05_050905/letters_050905_fm-1.html
HSL10645
Lexchin J.
Intellectual propety rights and the Canadian pharmaceutical marketplace: Where do we go from here?
International Journal of Health Services 2005;35(2):237 - 256
Link to source with long URL
HSL10646
Mintzes B, Lexchin J.
Do higher drug costs lead to better health?
Can J Clin Pharmacol 2005 Win;12(1):e22-7
Link to source with long URL
HSL2
Mansfield P.
Accepting what we can learn from advertising's mirror of desire.
BMJ 2004 Dec 18;329(7480):1487-8
Link to source with long URL
HSL488
Jureidini J, Tonkin A, Mansfield PR.
TADS study raises concerns.
BMJ 2004 Dec 4;329(7478):1343-4
http://bmj.bmjjournals.com/cgi/content/full/329/7478/1343-d
HSL486
Light DW, Lexchin J.
Will lower drug prices jeopardize drug research? A policy fact sheet
Am J Bioeth 2004 Winter;4(1):1-4
Nil
HSL4929
Mansfield PR.
Safety Query.
Australian Doctor Weekly 2004 Nov 17(1)
HSL487
Mansfield PR, Henry D.
Misleading drug promotion--no sign of improvements.
Pharmacoepidemiol Drug Saf 2004 Nov;13(11):797-9
http://www3.interscience.wiley.com/cgi-bin/abstract/107632790/ABSTRACT
HSL416
Allen K, Mansfield P.
Changing attitudes to 'the change'.
Aust Fam Physician 2004 Nov;33(11):939-40
http://www.racgp.org.au/document.asp?id=15004
HSL6018
Mansfield PR.
Reform of incentives would help reduce harm from drug promotion
BMJ 2004 Oct 30;329(11)
http://bmj.bmjjournals.com/cgi/eletters/329/7473/998
HSL6019
Mansfield PR.
Reply to Stephen Black and Nicholas DeMartinis
2004 Oct 15;329(11)
http://bmj.bmjjournals.com/cgi/eletters/329/7468/748
HSL499
Mansfield PR.
Banned drug's world of faceless victims
The Independent Weekly (Adelaide) 2004 Oct 10-16(11)
HSL6020
Mansfield PR, Tonkin AL, Jureidini JN.
Antidepressants do less good than harm for children and adolescents
BMJ 2004 Oct 8;329(11)
http://bmj.bmjjournals.com/cgi/eletters/329/7470/809
HSL1889
Mansfield PR.
A 5 minute read re drug promotion: RCT
Poster presented at 8th World Congress on Clinical Pharmacology & Therapeutics (CPT2004) Brisbane 2004 Aug 1-6(11)
HSL1358
Toop L, Richards D.
Physicians' negative views of direct-to-consumer advertising (DTCA): the international evidence grows.
N Z Med J 2004 Jun 4;117(1195):U905
HSL6021
Mansfield PR.
Clarification and Update for AdWatch on Nexium dialogue
BMJ 2004 Apr 30;328(1195)
http://bmj.bmjjournals.com/cgi/eletters/328/7447/1035-a
HSL257
Rogers WA, Mansfield PR, Braunack-Mayer AJ, Jureidini JN.
The ethics of pharmaceutical industry relationships with medical students.
Med J Aust 2004 Apr 19;180(8):411-4
http://www.mja.com.au/public/issues/180_08_190404/rog10715_fm.html
HSL258
Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL.
Efficacy and safety of antidepressants for children and adolescents.
BMJ 2004 Apr 10;328(7444):879-83
http://bmj.com/cgi/content/full/328/7444/879
HSL1660
Timimi S, Moncrieff J, Jureidini J, Leo J, Cohen D, Whitfield C, Double D, Bindman J, Andrews H, Asen E, Bracken P, Duncan B, Dunlap M, Albert G, Green M, Greening T, Hill J, Huws R, Karon B, Kean B, McCubbin M, Miatra B, Mosher L, Parry S, DuBose Ravenel
A critique of the international consensus statement on ADHD.
Clin Child Fam Psychol Rev 2004 Mar;7(1):59-63
HSL4957
Ong A, Mansfield PR.
Controversies: Should free drug samples be banned?
Australian Doctor Weekly 2004 Feb 6(1)
HSL489
Svensson S, Mansfield PR.
Escitalopram: superior to citalopram or a chiral chimera?
Psychother Psychosom 2004 Jan-Feb;73(1):10-6
Link to source with long URL
HSL490
Mansfield P, Henry D, Tonkin A.
Single-enantiomer drugs: elegant science, disappointing effects.
Clin Pharmacokinet 2004;43(5):287-90
Link to source with long URL
HSL11941
Medawar C, Herxheimer A.
A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine
The International Journal of Risk and Safety in Medicine 2004;16(1):5-19
Link to source with long URL
HSL1413
Mansfield PR.
Healthy Skepticism's new AdWatch: understanding drug promotion.
Med J Aust 2003 Dec 1-15;179(11-12):644-5
http://www.mja.com.au/public/issues/179_11_011203/man10667_fm.html
HSL1036
Jureidini J, Mansfield P, Menkes D.
The statin wars.
Lancet 2003 Nov 29;362(9398):1855
HSL1037
Katz D, Mansfield P, Goodman R, Tiefer L, Merz J.
Psychological aspects of gifts from drug companies.
JAMA 2003 Nov 12;290(18):2404-5
http://jama.ama-assn.org/cgi/content/full/290/18/2404-b
HSL4959
Carter H, Mansfield P.
Eye on ads.
Australian Doctor Weekly 2003 Nov 5(18)
HSL14104
Moncrieff J, Double D.
Double blind random bluff.
Ment Health Today 2003 Nov;:24-6(18)
http://www.ncbi.nlm.nih.gov/pubmed/14689600
HSL565
Mansfield PR.
Healthy scepticism.
Aust Fam Physician 2003 Oct;32(10):777
Nil
HSL415
Mansfield PR, Mintzes B.
Direct-to-consumer advertising is more profitable if it is misleading.
N Z Med J 2003 Sep 26;116(1182):U610
http://www.nzma.org.nz/journal/116-1182/610/
HSL2240
Mintzes B, Barer ML, Kravitz RL, Bassett K, Lexchin J, Kazanjian A, Evans RG, Pan R, Marion SA.
How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA
CMAJ. 2003 Sep 2;169(5):405-12
http://www.cmaj.ca/cgi/content/full/169/5/405
HSL6023
Mansfield PR.
Drug marketing deserves recognition
BMJ 2003 Aug 28;327(5)
http://bmj.bmjjournals.com/cgi/eletters/327/7413/468-d
HSL6413
Toop L, Richards D, Saunders B.
New Zealand deserves better. Direct-to-consumer advertising (DTCA) of prescription medicines in New Zealand: for health or for profit?
N Z Med J. 2003 Aug 22;116(1180):U556
HSL4962
Mansfield PR.
Gifts must go
Australian Doctor Weekly 2003 Aug 21(1180)
HSL1038
Jureidini J, Mansfield P.
The journal and drug advertising.
Aust N Z J Psychiatry 2003 Aug;37(4):495
HSL4964
Mansfield PR, Mak HK.
Drug reps: friend or foe?
Australian Doctor Weekly 2003 Jun 24(4)
HSL566
Mansfield PR.
Bribes for doctors: a gift for bioethicists?
Am J Bioeth 2003 Summer;3(3):47-8
Nil
HSL1439
Fugh-Berman A.
"Bust enhancing" herbal products.
Obstet Gynecol 2003 Jun;101(6):1345-9
http://www.greenjournal.org/cgi/content/full/101/6/1345
HSL1417
Lexchin J, Bero LA, Djulbegovic B, Clark O.
Pharmaceutical industry sponsorship and research outcome and quality: systematic review.
BMJ 2003 May 31;326(7400):1167-70
http://bmj.bmjjournals.com/cgi/content/full/326/7400/1167
HSL6024
Mansfield PR.
Free offer for all BMJ readers from Healthy Skepticism
BMJ 2003 May 30;326(7400)
http://bmj.bmjjournals.com/cgi/eletters/326/7400/1205
HSL1661
Jureidini J, Tonkin A.
Paroxetine in major depression.
J Am Acad Child Adolesc Psychiatry 2003 May;42(5):514
Link to source with long URL
HSL1459
Cassels A, Hughes MA, Cole C, Mintzes B, Lexchin J, McCormack JP.
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.
CMAJ 2003 Apr 29;168(9):1133-7
http://www.cmaj.ca/cgi/content/full/168/9/1133
HSL1658
Jureidini JN, Tonkin AL.
Clinical practice guidelines for depression in young people.
Med J Aust 2003 Mar 17;178(6):300
http://www.mja.com.au/public/issues/178_06_170303/letters_170303-5.html
HSL1412
Mansfield PR, Lexchin J, Vitry A, Doecke CJ, Svensson S.
Drug advertising in medical journals.
Lancet 2003 Mar 8;361(9360):879
Link to source with long URL
HSL6145
Russell FM, Shann F, Curtis N, Mulholland K.
Evidence on the use of paracetamol in febrile children.
Bull World Health Organ 2003;81(5):367-72
Link to source with long URL
HSL2623
Jureidini J, Mansfield PR.
Avoiding competing interests
BMJ 2002 Dec 27;325(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL2248
Vitry AI, Hurley E.
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors.
Med J Aust 2002 Nov 18;177(10):572-3
http://www.mja.com.au/public/issues/177_10_181102/vitry_181102.html
HSL1662
Jureidini J.
Does the International Consensus Statement on ADHD leave room for healthy scepticism?
Eur Child Adolesc Psychiatry 2002 Oct;11(5):240
HSL2216
Molloy W, Strang D, Guyatt G, Lexchin J, Bedard M, Dubois S, Russo R.
Assessing the quality of drug detailing.
J Clin Epidemiol 2002 Aug;55(8):825-32
HSL6415
Toop L, Richards D.
DTCA in New Zealand: the challenge of finding an acceptable balance
Br J Gen Pract. 2002 Apr 1;52(477):341
HSL6146
Shann F.
Research in developing countries.
N Engl J Med 2002 Feb 21;346(8):627-8
HSL2512
WHO Department of Essential Drugs & Medicines Policy
Drug Promotion Database
: WHO Department of Essential Drugs & Medicines Policy; 2002(8)
http://www.drugpromo.info/
HSL113
Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, et al.
Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey
BMJ 2002;324(8):278-279
http://bmj.bmjjournals.com/cgi/content/full/324/7332/278
HSL14024
Lexchin J, Mintzes B.
Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No
Journal of Public Policy and Marketing 2002;21(2):194-201
http://www.marketingpower.com/content18627.php
HSL6147
Shann F.
Uses of error: the wrong research costs lives.
Lancet 2001 May 26;357(9269):1691
http://linkinghub.elsevier.com/retrieve/pii/S0140673600048790
HSL2521
Jureidini J, Mansfield P.
Does drug promotion adversely influence doctors’ abilities to make the best decisions for patients?
Australasian Psychiatry 2001;9(9269):95-99
Link to source with long URL
HSL120
Vlassov V, Mansfield P, Lexchin J, Vlassova A.
Do drug advertisements in Russian medical journals provide essential information for safe prescribing?
West J Med 2001;174(9269):391-394
Nil
HSL7560
Gifts: a transcript of a television report
MaLAM International News 2000 Sep-Oct;18(9-10):1-4
HSL1032
Irwig LM, Loy CT, Chapman S, Glasziou PP, Mansfield PR, Salkeld GP, Walton MM.
!nform test kits distributed with the MJA.
Med J Aust 2000 May 15;172(10):518-9
HSL2609
Roughead L, Semple S, Vitry A.
The Value of Pharmacist Professional Services in the Community: A systematic review of the literature 1990-2002
2000(10)
HSL1221
Lexchin J.
Don't bite the hand that feeds you.
West J Med 1999 Oct;171(4):238-9
Link to source with long URL
HSL7488
Memoirs of methods used to sell drugs
MaLAM International News 1999 Mar-Apr;17(3-4):1-6
HSL7485
Advertising of antibacterials
Health Skepticism 1999 Feb;2(2):1-5
HSL7483
Advertising of CCBs for hypertension
Health Skepticism 1999 Jan;2(1):3-4
HSL532
Lexchin J.
Drug not considered a first-line agent.
Can Fam Physician 1998 Nov;44(1):2376
Nil
HSL7427
ACE inhibitors
Health Skepticism 1998 Nov;1(1):3-4
HSL534
Lexchin J.
Intellectual property rights and drug prices.
Lancet 1998 Aug 15;352(9127):582
Link to source with long URL
HSL531
Lexchin J.
Residents and pharmaceutical representatives.
Can Fam Physician 1998 Jul;44:1448(9127)
Nil
HSL7411
MaLAM letter follow up—MaLAM apologises but we remain concerned about thepromotion of Atarax
MaLAM International News 1998 Jul-Aug;16(7-8):1-5
HSL533
Lexchin J.
Improving the appropriateness of physician prescribing.
Int J Health Serv 1998;28(2):253-67
Nil
HSL1829
Mansfield PR.
MaLAM, a medical lobby for appropriate marketing of pharmaceuticals.
Med J Aust 1997 Dec 1-15;167(11-12):590-2
http://www.mja.com.au/public/issues/xmas/mansfield/mansfield.html
HSL7370
Mansfield P, Vitry A.
Re: the promotion of prescription products in Australia
1997 Dec(11-12)
HSL560
Vitry A, Mansfield P.
Drug advertisements in medical journals.
Lancet 1997 Nov 15;350(9089):1477-8
Link to source with long URL
HSL705
Lexchin J.
Code of marketing practices.Voluntary self-regulation for the Pharmaceutical Manufacturers Association of Canada
Can Fam Physician. 1997 11 01;43(9089)
HSL2218
Lexchin J.
What information do physicians receive from pharmaceutical representatives?
Can Fam Physician 1997 May;43(9089):941-5
Nil
HSL530
Lexchin J.
[Pharmaceutic regulation and inadequate drug prescription in Canada: the case of psychotropic drugs in the 1960s and early 1970s]
Sante Ment Que. 1997 Spring;22(1):283-300
Nil
HSL707
Lexchin J.
Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines?
CMAJ 1997 Feb 1;156(3):351-6
http://www.cmaj.ca/cgi/reprint/156/3/351
HSL677
Shear NH, Black F, Lexchin J.
Physician-detailer interaction—II.
Can J Clin Pharmacol 1997;4(1):10
Nil
HSL697
Mansfield P, Lexchin J.
MaLAM: networking for scientific integrity in drug promotion.
Essential Drugs Monitor 1997(24):5
http://healthyskepticism.org/library/EDM/24/Page5.pdf
HSL699
Mansfield P.
Can health professionals lobby drug companies to upgrade from misleading promotion to reliable service?
Australian Prescriber 1997;20(Supp 1):150
Nil
HSL706
Lexchin J.
Recent progress in drug advertising
Can Fam Physician 1997;43(Supp 1):1041-1042
HSL747
Vitry A, Mansfield P.
Promotion of Coversyl by Servier.
Lancet 1996 May 18;347(9012):1411
HSL805
Anderson GM, Lexchin J.
Strategies for improving prescribing practice.
CMAJ 1996 Apr 1;154(7):1013-7
http://www.cma.ca/cmaj/vol-154/1013e.htm
HSL748
Vitry A.
Pharmaceutical promotion: drug advertising affects your prescribing
Australian Prescriber 1996;19(7):103
HSL759
Shear NH, Black F, Lexchin J.
Examining the physician-detailer interaction
Can J Clin Pharmacol 1996;3(4):175-179
HSL774
Lexchin J.
Direct to consumer advertising of prescription drugs: the next steps
Can J Clin Pharmacol 1996;3(2):65
HSL498
Lexchin J.
Deception by design: Pharmaceutical promotion in the Third World
Penang: Consumers International; 1995(2)
Nil
HSL834
Lexchin J.
Is there a bias in industry supported clinical research
Can J Clin Pharmacol 1995;2(2):15-18
HSL6723
Lexchin J.
Agents against pediatric diarrhea. Assessing the information companies supply to Canadian physicians
Can Fam Physician. 1994 Dec 01;40(2):2082-7
HSL6729
Mansfield PR.
MaLAM: encouraging trustworthy drug promotion
Essential Drugs Monitor 1994(17):6
HSL2522
Lexchin J.
Interactions between physicians and the pharmaceutical industry: what does the literature say?
CMAJ 1993 Nov 15;149(10):1401-7
Link to source with long URL
HSL5696
Lexchin J.
Physicians and drug companies interact.
Can Fam Physician 1993 Sep 01;39(10):1881-2
HSL5132
Re: the promotion of aspirin
1992 Nov 1(10)
HSL2407
Mansfield PR.
Classifying improvements to drug marketing and justifications for claims of efficacy.
Int J Risk Safety Med 1991;2(10):171-84
Nil
HSL4457
Wade VA, Mansfield PR, McDonald PJ.
Drug companies' evidence to justify advertising.
Lancet 1989 Nov 25;2(8674):1261-3
HSL1035
Mansfield PR.
Drug advertising.
Lancet 1989 May 20;1(8647):1137-8
HSL1040
Mansfield P.
Diflunisal advertising.
Med J Aust 1988 Apr 18;148(8):418,
HSL2408
Mansfield PR.
Drug Advertising
Med J Aust 1987 Jun 15;146(12):660-661
HSL1041
Mansfield P.
Phenylbutazone.
Med J Aust 1986 Jan 6;144(1):55
HSL1042
Mansfield P.
Phenylbutazone.
Med J Aust 1985 Sep 2;143(5):219-20
HSL9166
Jureidini JN, Mansfield PR.
The scope of the problem of the relationship between drug companies and doctors
Maitra B, Timimi S. Critical Voices in Child and Adolescent Mental Health London: Free Association Books; 2006(5)
http://www.fabooks.com/book.php?id=434